MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Search

Quidel Corp

Atidarymo kaina

33.29 -0.51

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

32.31

Max

33.75

Pagrindiniai rodikliai

By Trading Economics

Darbuotojai

6,600

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

-20.59% downside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

114M

1.7B

Ankstesnė atidarymo kaina

33.8

Ankstesnė uždarymo kaina

33.29

Quidel Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-07 23:11; UTC

Uždarbis

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

2026-01-07 22:55; UTC

Pagrindinės rinkos jėgos

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

2026-01-07 21:39; UTC

Pagrindinės rinkos jėgos

Raytheon Down Following Trump Post Criticizing Company

2026-01-07 20:13; UTC

Pagrindinės rinkos jėgos

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

2026-01-07 20:03; UTC

Pagrindinės rinkos jėgos

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

2026-01-07 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-07 23:46; UTC

Rinkos pokalbiai

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

2026-01-07 23:42; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

2026-01-07 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

2026-01-07 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

2026-01-07 22:48; UTC

Rinkos pokalbiai

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

2026-01-07 22:46; UTC

Uždarbis

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

2026-01-07 22:45; UTC

Uždarbis

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

2026-01-07 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Revolution Medicines Draws Takeover Interest -- 2nd Update

2026-01-07 22:42; UTC

Uždarbis

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

2026-01-07 22:41; UTC

Uždarbis

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

2026-01-07 22:41; UTC

Uždarbis

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

2026-01-07 22:40; UTC

Pagrindinės rinkos jėgos

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

2026-01-07 22:31; UTC

Rinkos pokalbiai

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

2026-01-07 22:22; UTC

Rinkos pokalbiai

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

2026-01-07 22:01; UTC

Rinkos pokalbiai

Valuations of New Zealand Property Stocks Supportive -- Market Talk

2026-01-07 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-07 21:46; UTC

Rinkos pokalbiai

Northern Star's Revised Guidance Looks Achievable -- Market Talk

2026-01-07 21:22; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

2026-01-07 21:18; UTC

Įsigijimai, susijungimai, perėmimai

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

2026-01-07 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

2026-01-07 20:29; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie Near Deal for Revolution Medicines -- Update

2026-01-07 20:27; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2026-01-07 19:58; UTC

Rinkos pokalbiai

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

2026-01-07 19:48; UTC

Pagrindinės rinkos jėgos

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Akcijų palyginimas

Kainos pokytis

Quidel Corp Prognozė

Kainos tikslas

By TipRanks

-20.59% į apačią

12 mėnesių prognozė

Vidutinis 26.5 USD  -20.59%

Aukščiausias 31 USD

Žemiausias 22 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Quidel Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

1

Pirkti

3

Laikyti

1

Parduoti

Finansinės naujienos

$

Apie bendrovę Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat